NCT00034463已完成1 期
A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis of metastatic or locally advanced cancer
- •Prior chemotherapy is allowed
- •Adequate bone marrow, liver and kidney function
排除标准
- •Prior treatment with ALIMTA
- •Brain metastasis
- •Pregnancy or breast feeding
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung CancerNon-Small Cell Lung CancerNCT00078260Eli Lilly and Company589
进行中（未招募）
不适用
A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer(Sweden will participate in Phase 2 of this trial, only)platinum sensitive recurrent ovarian or primary peritoneal cancerMedDRA version: 8.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSEUCTR2004-002782-20-SEEli Lilly and Company Limited85
进行中（未招募）
不适用
A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal CancerEUCTR2004-002782-20-DEEli Lilly and Company Limited110
已完成
2 期
Pemetrexed as First Line Chemotherapy for Advanced Breast CancerBreast CancerNCT00065533Eli Lilly and Company92
已完成
1 期
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerPrimary Peritoneal CancerOvarian CancerNCT00489359Eli Lilly and Company86